Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients

Diabetes & Metabolism Journal
Antoni Sicras-Mainar, Ruth Navarro-Artieda

Abstract

To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice. An observational, retrospective study was performed. Patients aged ≥30 years treated with metformin who initiated a second oral antidiabetic treatment in 2009 to 2010 were included. Two groups of patients were analysed: metformin+DPP-4 inhibitors and other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated hemoglobin< 7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for 2 years. We included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin+DPP-4 inhibitors and 260 patients received metformin+other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%), and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (P<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), P=0.001. Despite the limitations of the study, patient...Continue Reading

References

Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber
Feb 28, 2004·Diabetes Care·Johan FageruddUNKNOWN FinnDiane Study Group
Feb 15, 2011·International Journal of Clinical Practice·C J Bailey, M Kodack
Feb 2, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·György JermendyBéla Merkely
Nov 22, 2012·Current Diabetes Reviews·Peter Noel Van Buren, Robert Toto
Dec 18, 2012·Expert Opinion on Drug Safety·Stephanie Aleskow SteinStephen N Davis
Jan 15, 2013·Vascular Pharmacology·Mandeep Kumar Arora, Umesh Kumar Singh
Feb 5, 2013·Vascular Health and Risk Management·Valentina LukashevichWolfgang Kothny
Apr 17, 2013·The Journal of Clinical Endocrinology and Metabolism·Elizabeth R SeaquistUNKNOWN Endocrine Society

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.